Fact CheckerSign in

NCT06477640Active, not recruiting

Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension

Source: ClinicalTrials.gov · Last updated 15 Jul 2026

Brief summary (registry, in English)

The purpose of this study is to evaluate whether a home rehabilitation program for patients diagnosed with Pulmonary Arterial Hypertension (PAH) will decrease Cardiac Effort (number of heart beats used during 6-minute walk test/walk distance) and improve quality of life. Ultimately, this information could help improve the management of patients with PAH.

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
55 (estimated)
First submitted
21 Jun 2024
Start date
29 Jul 2024
Primary completion date
31 Dec 2026
Lead sponsor
University of Rochester
NCT number
NCT06477640

What you commit to

  • Study type: Interventional
  • Planned participants: 55
  • From 29 Jul 2024 to the primary completion date, 31 Dec 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Oxygen therapy of more than 6 L/min at rest.

Other illness

  • Pulmonary Hypertension Groups 2-5.

Other

  • Pregnancy.
  • Resting tachycardia \>120 beats/m during screening.
  • Inability to walk.
  • WHO Functional Class IV
  • Lack of access to email or text messaging.
  • Inability to follow daily instructions. including the two home 6-minute walk tests during the initial monitoring period. This is to show compliance with the protocol.
  • Participating in a self-reported rehabilitation or exercise program.
  • Principal Investigator discretion

Who the study is looking for

  • Follows at University of Rochester Medical Center Pulmonary Hypertension Clinic.
  • Adult patients (\>18 years old) with right heart catheterization confirmed pulmonary hypertension (PAH) on stable vasodilator dosing for at least 30 days. No planned titrations will occur during the 12-week study. If during the study, the treating physician feels it is necessary for safety reasons to adjust dosing, the subject will remain in their assigned group.
  • Access to a smart phone or email to receive daily messages. If patients do not have access to either, we will offer a smartphone with cellular service for use during the study to receive daily messages.
  • Clinically stable by the investigator (i.e., we will not enroll patients who endorse ongoing improvement or clinical worsening at enrollment).
  • The treating investigator (Dr. Lachant or Dr. White) will review the clinical data of an eligible patient and establish them as safe to participate prior to approaching the patient for enrollment (i.e. not in decompensated heart failure or with recurrent pre-syncopal episodes prior to enrollment).

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University of Rochester Medical Center
Coordinator of this site? Confirm its status
RochesterUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.